Semaglutide for atrial fibrillation and weight loss
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your BMI is 30 or higher (meaning you have obesity).
- You have atrial fibrillation (AF) that comes and goes or lasts for a while.
- You have not used GLP-1 medications (like Ozempic or Wegovy) or weight-loss drugs in the last 90 days.
- You have not had weight loss surgery, or lost more than 11 pounds in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking semaglutide (a weight-loss medication) before a catheter ablation procedure helps improve outcomes for people with atrial fibrillation and excess weight. If you qualify, it might help reduce the chance of the abnormal heart rhythm coming back.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
Hear when a new Overweight or Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.